Skip to main content

Table 2 Comparison of CR rate among UGT1A1 genotypes after 2 courses of Ara-C based chemotherapy

From: Influence of UGT1A1 polymorphisms on the outcome of acute myeloid leukemia patients treated with cytarabine-base regimens

SNP Genotype Total, n CR, n (%) Non-CR, n (%) OR (95% CI) P value
UGT1A1*6 *1/*1 471 315 (66.9) 156 (33.1) 1.00 (reference)  
*1/*6 202 155 (76.7) 47 (23.3) 0.612 (0.419–0.894) 0.011
*6/*6 24 19 (79.2) 5 (20.8) 0.531 (0.195–1.450) 0.353
*6/ 226 174 (77.0) 52 (23.0) 0.604 (0.419–0.869) 0.007
UGT1A1*28 *1/*1 553 379 (68.5) 174 (31.5) 1.00 (reference)  
*1/*28 130 97 (74.6) 33 (25.4) 0.741 (0.480–1.144) 0.176
*28/*28 14 13 (92.9) 1 (7.1) 0.168 (0.022–1.291) 0.086
*28/ 144 110 (76.4) 34 (23.6) 0.673 (0.440–1.029) 0.068
Combined genotypes *1/*1 for both loci 359 229 (63.8) 130 (36.2) 1.00 (reference)  
*6/− alone 194 150 (77.3) 44 (22.7) 0.517 (0.347–0.770) 0.001
*28/− alone 112 86 (76.8) 26 (23.2) 0.533 (0.327–0.868) 0.011
*6/− and *28/ 32 24 (75.0) 8 (25.0) 0.587 (0.256–1.345) 0.208
*6/− or *28/ 338 260 (76.9) 78 (23.1) 0.528 (0.379–0.737) 1.7 × 10−4